Equities research analysts expect that Celsion Co. (NASDAQ:CLSN – Get Rating) will announce sales of $110,000.00 for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Celsion’s earnings. The lowest sales estimate is $100,000.00 and the highest is $130,000.00. Celsion posted sales of $130,000.00 in the same quarter last year, which would indicate a negative year-over-year growth rate of 15.4%. The company is scheduled to issue its next earnings report on Monday, January 1st.
On average, analysts expect that Celsion will report full-year sales of $500,000.00 for the current year. For the next financial year, analysts expect that the firm will report sales of $500,000.00. Zacks’ sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Celsion.
A number of equities research analysts recently weighed in on CLSN shares. StockNews.com assumed coverage on Celsion in a research report on Wednesday. They set a “hold” rating on the stock. HC Wainwright assumed coverage on Celsion in a report on Wednesday, April 13th. They issued a “buy” rating and a $16.00 target price on the stock.
Shares of CLSN stock opened at $2.94 on Friday. The company has a current ratio of 7.67, a quick ratio of 7.67 and a debt-to-equity ratio of 0.10. Celsion has a 1 year low of $2.81 and a 1 year high of $23.25. The stock has a market cap of $16.97 million, a P/E ratio of -0.75 and a beta of 2.11. The stock has a 50 day simple moving average of $4.62 and a 200 day simple moving average of $8.03.
About Celsion (Get Rating)
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.
- Get a free copy of the StockNews.com research report on Celsion (CLSN)
- Iridium Communications Stock is Ready to Return to Orbit
- O’Reilly Automotive Hits A Pothole
- There’s An Institutional Floor In Keurig Dr. Pepper
- Ford Falls Despite Optimistic Outlook
- Harley-Davidson Skids Into A Buying Opportunity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.